The 2015 US Food and Drug Administration Pregnancy and Lactation Labeling Rule

被引:36
|
作者
Brucker, Mary C. [1 ]
King, Tekoa L. [2 ]
机构
[1] Georgetown Univ, Sch Nursing & Hlth Sci, Washington, DC USA
[2] Univ Calif San Francisco, Sch Nursing, San Francisco, CA 94143 USA
关键词
MEDICATIONS; HISTORY;
D O I
10.1111/jmwh.12611
中图分类号
R47 [护理学];
学科分类号
1011 ;
摘要
As of 2015, the US Food and Drug Administration (FDA) discontinued the pregnancy risk categories (ABCDX) that had been used to denote the putative safety of drugs for use among pregnant women. The ABCDX system has been replaced by the FDA Pregnancy and Lactation Labeling Rule (PLLR) that requires narrative text to describe risk information, clinical considerations, and background data for the drug. The new rule includes 3 overarching categories: 1) pregnancy, which includes labor and birth; 2) lactation; and 3) females and males of reproductive potential. This article reviews the key components of the PLLR and clinical implications, and provides resources for clinicians who prescribe drugs for women of reproductive age. (C) 2017 by the American College of Nurse-Midwives.
引用
收藏
页码:308 / 316
页数:9
相关论文
共 50 条
  • [41] Urokinase and the US food and drug administration
    Ouriel, K
    JOURNAL OF VASCULAR SURGERY, 1999, 30 (05) : 957 - 958
  • [42] Independence at the US Food and Drug Administration
    不详
    LANCET, 2006, 367 (9523): : 1630 - 1630
  • [43] Transparency at the US Food and Drug Administration
    Califf, Robert M.
    JOURNAL OF LAW MEDICINE & ETHICS, 2017, 45 : 24 - 28
  • [45] Introduction to the new prescription drug labeling by the Food and Drug Administration
    Lal, Renu
    Kremzner, Mary
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2007, 64 (23) : 2488 - 2494
  • [46] US Food and Drug Administration Regulations and Birth Defect Prevention: It's More Than Labeling
    Johnson, T. N.
    BIRTH DEFECTS RESEARCH, 2018, 110 (09): : 737 - 737
  • [47] Communication of Survival Data in US Food and Drug Administration-Approved Labeling of Cancer Drugs
    Naci, Huseyin
    Guan, Xiaodong
    Woloshin, Steven
    Xu, Ziyue
    Wagner, Anita K.
    JAMA INTERNAL MEDICINE, 2021, 181 (11) : 1521 - 1522
  • [48] Pediatric Efficacy Extrapolation in Drug Development Submitted to the US Food and Drug Administration 2015-2020
    Samuels, Sherbet
    Park, Kyunghun
    Bhatt-Mehta, Varsha
    Sun, Haihao
    Mulugeta, Yeruk
    Yao, Lynne
    Green, Dionna J.
    Burckart, Gilbert J.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 63 (03): : 307 - 313
  • [49] US Food and Drug Administration Reports of Pregnancy and Pregnancy-Related Adverse Events Associated With Isotretinoin
    Tkachenko, Elizabeth
    Singer, Sean
    Sharma, Priyank
    Barbieri, John
    Mostaghimi, Arash
    JAMA DERMATOLOGY, 2019, 155 (10) : 1175 - 1179
  • [50] Analysis of US Food and Drug Administration Food Allergen Recalls after Implementation of the Food Allergen Labeling and Consumer Protection Act
    Gendel, Steven M.
    Zhu, Jianmei
    JOURNAL OF FOOD PROTECTION, 2013, 76 (11) : 1933 - 1938